Lineage Cell Therapeutics, INC Form 4 insider transactions

Director Don M Bailey acquired 75,000 stock options in Lineage Cell Therapeutics, Inc. on July 1, 2024.

Director Anula Jayasuriya acquired 75,000 stock options in Lineage Cell Therapeutics on July 1, 2024, according to a Form 4 filing.

Deborah J Andrews, a director at Lineage Cell Therapeutics, acquired 75,000 stock options on July 1, 2024.

Director Dipti Amin acquired 75,000 stock options in Lineage Cell Therapeutics on July 1, 2024, according to a Form 4 filing.

Director Neal C. Bradsher reports the acquisition and disposal of options to purchase common shares of Lineage Cell Therapeutics.

Lineage Cell Therapeutics' CEO, Brian M. Culley, acquired 10,000 shares of the company's common stock at an average price of $1.05 per share on May 24, 2024.

Brian M. Culley, President and CEO of Lineage Cell Therapeutics, acquired 1,900,000 employee stock options on March 7, 2024.

George A. Samuel III, General Counsel/Secretary of Lineage Cell Therapeutics, acquired 650,000 employee stock options on March 7, 2024.

Jill Ann Howe, CFO of Lineage Cell Therapeutics, was granted 650,000 employee stock options on March 7, 2024.